Overview
Biomarker discovery is the systematic process of identifying and validating measurable biological indicators, molecules or characteristics that signal a normal or pathological state, or a response to treatment. Biomarkers may be proteins, nucleic acids such as microRNAs, metabolites, or genetic and cellular features, and they are used to detect disease early, classify and stage it, predict risk and prognosis, and guide and monitor therapy. Discovery typically proceeds from high-throughput screening of biological samples through candidate identification, analytical and clinical validation, and assessment of utility, drawing on proteomics, genomics, and increasingly on advanced experimental and computational platforms. Research in this area surveys proteomic and genomic techniques in medical research and their application to cancer, diagnostics, and personalized medicine, and describes high-throughput disease-modelling platforms for cancer biomarker development. Studies that use a reproducible, ion-current-based proteomics strategy to map the response to lapatinib treatment illustrate the discovery of protein markers, while work employing microfluidic assays and digital PCR to quantify microRNAs for the diagnostic screening of colon cancer demonstrates nucleic-acid biomarker development for low-resource settings. Analysis of dynamic plasma microRNA expression in melanoma in relation to progression, PD-L1 status, and survival links candidate markers to clinical outcome. Together these threads span the proteomic and genomic identification, validation, and clinical application of biomarkers, underpinning early diagnosis, prognosis, and the personalization of treatment.
Research published in this journal
9 peer-reviewed articles, ranked by relevance. Each links to its DOI.
High-Throughput Complex Disease Modeling for Ethical Drug Discovery: Clinical Relevance of a NAM Platform for Cancer Biomarker Development
Determination of the Proteomic Response to Lapatinib Treatment using a Comprehensive and Reproducible Ion-Current-Based Proteomics Strategy
Use of Microfluidic Assays to Develop Reliable and Economic Nucleic Acid Application Technologies, Employing MicroRNAs for the Diagnostic Screening of Colon Cancer in Human Stool in Low-Resource Settings
Use of Microfluidic Assays to Develop Reliable and Economic Nucleic Acid Application Technologies, Employing MicroRNAs for the Diagnostic Screening of Colon Cancer in Human Stool in Low-Resource Settings
Dynamic MicroRNA-Expression in Plasma of Melanoma Patients Correlates With Progression, PD-L1 Status and Overall Survival
Quantification of Micrornas by Absolute Dpcr for the Diagnostic Screening of Colon Cancer
Molecular Biomarkers: A Brief Review
How this research is being cited
The 9 articles above have been cited 20 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2026 · Human Gene
-
2026 · Biochemical Pharmacology
-
2026 · Alcohol and Alcoholism
-
2026 · BMC Bioinformatics
-
Hami Hemati et al. · 2025 · Brain, behavior, and immunity
-
Diagnostic and Therapeutic Potential of Selected microRNAs in Colorectal Cancer: A Literature Review2025 · Cancers
-
Diagnostic and Therapeutic Potential of Selected microRNAs in Colorectal Cancer: A Literature Review2025 · Cancers
-
2025 · Brain Behavior and Immunity
A sample of recent works citing this journal's research on Biomarker Discovery, linking to each citing work.